Your browser is no longer supported. Please, upgrade your browser.
Veracyte, Inc.
Index- P/E- EPS (ttm)-1.14 Insider Own0.20% Shs Outstand71.04M Perf Week-18.22%
Market Cap1.92B Forward P/E- EPS next Y-0.57 Insider Trans-25.45% Shs Float70.47M Perf Month-28.23%
Income-73.10M PEG- EPS next Q-0.16 Inst Own- Short Float4.91% Perf Quarter-38.45%
Sales186.70M P/S10.27 EPS this Y-140.10% Inst Trans1.22% Short Ratio5.64 Perf Half Y-27.63%
Book/sh15.87 P/B1.75 EPS next Y51.30% ROA-7.90% Target Price61.38 Perf Year-47.96%
Cash/sh2.38 P/C11.69 EPS next 5Y- ROE-8.40% 52W Range28.42 - 86.03 Perf YTD-32.55%
Dividend- P/FCF- EPS past 5Y12.70% ROI-8.40% 52W High-67.70% Beta0.89
Dividend %- Quick Ratio4.40 Sales past 5Y18.90% Gross Margin66.40% 52W Low-2.22% ATR3.22
Employees320 Current Ratio4.60 Sales Q/Q94.20% Oper. Margin-41.60% RSI (14)29.88 Volatility9.34% 9.08%
OptionableYes Debt/Eq0.00 EPS Q/Q-169.50% Profit Margin-39.10% Rel Volume1.20 Prev Close30.34
ShortableYes LT Debt/Eq0.00 EarningsNov 09 AMC Payout- Avg Volume612.48K Price27.79
Recom2.00 SMA20-26.63% SMA50-32.69% SMA200-35.41% Volume722,691 Change-8.40%
Jan-07-22Initiated Stephens Overweight $52
Nov-18-21Resumed Goldman Buy $60
Jun-15-21Initiated Raymond James Outperform $45
Feb-18-21Resumed Needham Buy $88
Jan-28-21Initiated Truist Buy $61
Nov-10-20Initiated KeyBanc Capital Markets Sector Weight $48
Sep-09-20Initiated Morgan Stanley Underweight $35
Jul-31-19Initiated Lake Street Buy $35
Jul-02-19Initiated Needham Buy $33
Nov-29-18Downgrade Janney Buy → Neutral
Oct-31-18Upgrade Janney Neutral → Buy
Nov-07-17Downgrade Piper Jaffray Overweight → Neutral
Nov-07-17Downgrade Janney Buy → Neutral
Aug-31-17Resumed BTIG Research Buy $13
Nov-14-16Resumed Leerink Partners Outperform $12
Dec-18-15Initiated Cantor Fitzgerald Buy $13
Jun-11-15Reiterated Leerink Partners Outperform $11 → $13
Nov-26-13Initiated William Blair Outperform
Jan-12-22 11:37AM  
Jan-06-22 08:30AM  
Dec-14-21 04:05PM  
Nov-24-21 04:32AM  
Nov-13-21 07:00AM  
Nov-11-21 11:45AM  
Nov-09-21 07:05PM  
Nov-05-21 08:15AM  
Nov-03-21 08:15AM  
Nov-02-21 03:01PM  
Oct-26-21 09:25AM  
Oct-25-21 04:26PM  
Oct-14-21 08:35AM  
Oct-13-21 08:55AM  
Oct-12-21 04:58PM  
Oct-11-21 07:39PM  
Oct-06-21 08:30AM  
Oct-05-21 08:20AM  
Sep-23-21 01:07AM  
Sep-14-21 04:05PM  
Sep-06-21 01:22PM  
Sep-03-21 12:28AM  
Sep-01-21 08:35AM  
Aug-31-21 08:15AM  
Aug-23-21 10:33AM  
Aug-03-21 08:00AM  
Jul-29-21 06:45PM  
Jul-27-21 04:05PM  
Jul-22-21 03:03PM  
Jul-21-21 11:51AM  
Jul-12-21 08:30AM  
Jul-08-21 04:05PM  
Jul-01-21 08:45AM  
Jun-21-21 07:47AM  
Jun-14-21 08:45AM  
Jun-09-21 07:18AM  
Jun-04-21 09:24AM  
Jun-02-21 04:27PM  
Jun-01-21 12:22PM  
May-26-21 03:00PM  
May-25-21 09:00AM  
May-19-21 05:00PM  
May-18-21 05:15PM  
May-14-21 04:35PM  
May-13-21 03:28AM  
May-10-21 06:50PM  
May-04-21 04:45PM  
Apr-29-21 08:30AM  
Apr-27-21 04:35PM  
Apr-20-21 01:00PM  
Apr-19-21 08:30AM  
Apr-15-21 04:05PM  
Apr-14-21 08:30AM  
Apr-03-21 06:12AM  
Apr-02-21 08:15AM  
Mar-22-21 08:15AM  
Mar-19-21 09:44AM  
Mar-15-21 08:30AM  
Mar-10-21 05:15PM  
Feb-18-21 04:05PM  
Feb-17-21 04:25PM  
Feb-16-21 10:13AM  
Feb-11-21 04:05PM  
Feb-10-21 08:15AM  
Feb-09-21 04:15PM  
Feb-08-21 07:00PM  
Feb-04-21 10:45PM  
Feb-03-21 04:32PM  
Jan-23-21 11:30PM  
Jan-06-21 02:00PM  
Dec-23-20 08:00AM  
Dec-22-20 08:52AM  
Dec-21-20 08:15AM  
Dec-16-20 12:00PM  
Dec-15-20 05:59PM  
Dec-11-20 10:00PM  
Dec-03-20 02:30PM  
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JONES EVAN/ FADirectorJan 11Option Exercise4.005,00020,00043,720Jan 13 04:51 PM
EASTHAM KARINDirectorDec 17Option Exercise12.125,00060,60013,720Dec 20 04:44 PM
EASTHAM KARINDirectorDec 17Sale45.005,000225,0008,720Dec 20 04:44 PM
Anderson Bonnie HExecutive ChairwomanDec 09Option Exercise8.8611,28699,99473,542Dec 10 04:42 PM
Kennedy Giulia CChief Scientific & Med OfficerDec 07Option Exercise25.226,125154,48154,037Dec 08 04:42 PM
Kennedy Giulia CChief Scientific & Med OfficerDec 07Sale40.226,125246,35647,912Dec 08 04:42 PM
Kennedy Giulia CChief Scientific & Med OfficerDec 06Option Exercise12.528,156102,13557,144Dec 08 04:42 PM
Kennedy Giulia CChief Scientific & Med OfficerDec 06Sale36.059,232332,78447,912Dec 08 04:42 PM
EASTHAM KARINDirectorNov 01Sale49.094,400215,9900Nov 03 05:19 PM
Anderson Bonnie HExecutive ChairwomanSep 17Sale50.182,600130,478217,478Sep 21 04:18 PM
Anderson Bonnie HExecutive ChairwomanSep 10Sale50.031,90095,050220,078Sep 14 04:37 PM
Kennedy Giulia CChief Scientific & Med OfficerSep 08Sale50.5392646,79150,049Sep 09 05:07 PM
Kennedy Giulia CChief Scientific & Med OfficerSep 07Option Exercise16.7712,531210,15463,506Sep 09 05:07 PM
Kennedy Giulia CChief Scientific & Med OfficerSep 07Sale50.5512,531633,40850,975Sep 09 05:07 PM
EASTHAM KARINDirectorAug 02Sale43.914,400193,1944,400Aug 04 04:19 PM
Kennedy Giulia CChief Scientific & Med OfficerJun 23Option Exercise24.694,375108,01956,262Jun 25 04:12 PM
Kennedy Giulia CChief Scientific & Med OfficerJun 23Sale39.754,375173,91451,887Jun 25 04:12 PM
Kennedy Giulia CChief Scientific & Med OfficerJun 04Option Exercise12.528,156102,13560,968Jun 08 04:38 PM
Kennedy Giulia CChief Scientific & Med OfficerJun 04Sale34.639,081314,51551,887Jun 08 04:38 PM
Holstein JensDirectorJun 03Buy35.192,00070,3892,000Jun 04 05:00 PM
Anderson Bonnie HChairman and CEOMay 17Option Exercise5.6114,06578,905192,013May 19 04:34 PM
EASTHAM KARINDirectorMay 03Sale48.274,427213,7008,800May 05 04:41 PM
Kennedy Giulia CChief Scientific & Med OfficerMar 04Option Exercise18.8030,970582,299105,739Mar 08 05:33 PM
Kennedy Giulia CChief Scientific & Med OfficerMar 04Sale49.3652,0152,567,27153,724Mar 08 05:33 PM
EASTHAM KARINDirectorFeb 25Option Exercise4.006,25025,0006,250Feb 26 04:45 PM
EASTHAM KARINDirectorFeb 25Sale60.706,250379,3590Feb 26 04:45 PM
JONES EVAN/ FADirectorJan 22Option Exercise2.365,00011,80030,000Jan 25 05:24 PM
Ho MarkPrincipal Accounting OfficerJan 20Option Exercise5.1652,500270,67571,434Jan 21 05:29 PM